Effects of 6 weeks of treatment with dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo‐controlled, exploratory study-Reference-Cited by-同舟云学术

Effects of 6 weeks of treatment with dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo‐controlled, exploratory study

Published:2021-03-12 Issue:7 Volume:23 Page:1505-1517
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Oldgren Jonas¹^ORCID,Laurila Sanna²³⁴,Åkerblom Axel¹,Latva‐Rasku Aino³,Rebelos Eleni³^ORCID,Isackson Henrik¹,Saarenhovi Maria³,Eriksson Olof⁵,Heurling Kerstin⁵,Johansson Edvin⁵,Wilderäng Ulrica⁶,Karlsson Cecilia⁶,Esterline Russell⁷,Ferrannini Ele⁸^ORCID,Oscarsson Jan⁶^ORCID,Nuutila Pirjo³^ORCID

Affiliation:

1. Uppsala Clinical Research Center and Department of Medical Sciences Uppsala University Uppsala Sweden

2. Heart Center Turku University Hospital Turku Finland

3. Turku PET Centre University of Turku and Turku University Hospital Turku Finland

4. Satakunta Central Hospital Pori Finland

5. Antaros Medical AB Mölndal Sweden

6. BioPharmaceuticals R&D, AstraZeneca Gothenburg Sweden

7. BioPharmaceuticals R&D, AstraZeneca Gaithersburg Maryland USA

8. Institute of Clinical Physiology, National Research Council Pisa Italy

Funder

AstraZeneca

Publisher